Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEACE2
2024-517622-25-00Phase 3Authorised
- Sponsor
- Unicancer
- Start
- Nov 2024
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 3
01
Overview
Phase 3, randomised trial of cabazitaxel in prostate cancer (PCa) (4 arms), sponsored by Unicancer. Primary endpoint: Prostate cancer-specific survival. Planned start Nov 2024; status: authorised.
02
Drugs
cabazitaxel
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2024-517622-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517622-25-00.